Previous close | 331.50 |
Open | 332.70 |
Bid | 334.40 x N/A |
Ask | 334.50 x N/A |
Day's range | 330.80 - 336.00 |
52-week range | 306.80 - 353.10 |
Volume | |
Avg. volume | 25,750,741 |
Market cap | 30.538B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 30.40 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.06 (1.79%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
Key Insights Using the 2 Stage Free Cash Flow to Equity, Haleon fair value estimate is UK£2.62 Haleon is estimated to...
AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.